Powered By Google
St. Jude Research >> ALL4 >> Table2

Supplementary Information

Gene-expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment.

Supplemental Table 2 : Patient characteristics.

Included were 173 patients categorized as resistant or sensitive to one or more of the four drugs. The sample size and the distribution of known prognostic factors (i.e., white blood cell count (WBC) and age at diagnosis; gender, and lineage) for each antileukemic agent are shown for (a) all patients and (b) the B-lineage ALL patients.

a.

Drug   N Age at diagnosis
[median in years]		 Gender WBC at diagnosis
[109/L]		 Lineage
Prednisolone Sensitive
Resistant		 66
27		 5.9
8.0
P=0.007*		 36M 30F
17M 10F
P=0.497 ‡		 43.0
19.9
P=0.314*		 54B 12T
20B  7T
P=0.408 ‡
Vincristine Sensitive
Resistant		 89
36		 6.0
6.7
P=0.651*		 54M 35F
20M 16F
P=0.689 ‡		 34.7
15.4
P=0.172*		 75B 14T
29B  7T
P=0.606 ‡
asparaginase Sensitive
Resistant		 81
45		 4.4
7.3
P=0.004*		 47M 34F
24M 21F
P=0.708 ‡		 30.0
28.3
P=0.729*		 66B 15T
40B  5T
P=0.320 ‡
Daunorubicin Sensitive
Resistant		 94
28		 4.6
7.7
P=0.031*		 57M 37F
17M 11F
P=1.0 ‡		 40.0
17.6
P=0.378*		 82B 12T
23B  5T
P=0.537 ‡

b

Drug   N Age at diagnosis
 [median in years]		 Gender WBC at diagnosis
[109/L]
Prednisolone Sensitive
Resistant		 54
20		 5.8
8.9
P=0.016*		 28M 26F
12M 8F
P=0.605 ‡		 33.1
8.3
P=0.012*
Vincristine Sensitive
Resistant		 75
29		 6.0
6.3
P=0.888*		 46M 29F
15M 14F
P=0.358 ‡		 25.6
9.9
P=0.016*
asparaginase Sensitive
Resistant		 66
40		 4.2
7.3
P=0.003*		 38M 28F
21M 19F
P=0.688 ‡		 23.2
18.5
P=0.732*
Daunorubicin Sensitive
Resistant		 82
23		 4.4
7.2
P=0.117*		 49M 33F
13M 10F
P=0.814 ‡		 26.8
16.3
P=0.275*

M=male, F=female; P-values determined by *Wilcoxon rank sum test ‡Fisher's exact test

< Previous | Next >